BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 22848414)

  • 1. IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia.
    Iacobucci I; Iraci N; Messina M; Lonetti A; Chiaretti S; Valli E; Ferrari A; Papayannidis C; Paoloni F; Vitale A; Storlazzi CT; Ottaviani E; Guadagnuolo V; Durante S; Vignetti M; Soverini S; Pane F; Foà R; Baccarani M; Müschen M; Perini G; Martinelli G
    PLoS One; 2012; 7(7):e40934. PubMed ID: 22848414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.
    Scheijen B; Boer JM; Marke R; Tijchon E; van Ingen Schenau D; Waanders E; van Emst L; van der Meer LT; Pieters R; Escherich G; Horstmann MA; Sonneveld E; Venn N; Sutton R; Dalla-Pozza L; Kuiper RP; Hoogerbrugge PM; den Boer ML; van Leeuwen FN
    Haematologica; 2017 Mar; 102(3):541-551. PubMed ID: 27979924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP).
    Iacobucci I; Storlazzi CT; Cilloni D; Lonetti A; Ottaviani E; Soverini S; Astolfi A; Chiaretti S; Vitale A; Messa F; Impera L; Baldazzi C; D'Addabbo P; Papayannidis C; Lonoce A; Colarossi S; Vignetti M; Piccaluga PP; Paolini S; Russo D; Pane F; Saglio G; Baccarani M; Foà R; Martinelli G
    Blood; 2009 Sep; 114(10):2159-67. PubMed ID: 19589926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular profiling of gene copy number abnormalities in key regulatory genes in high-risk B-lineage acute lymphoblastic leukemia: frequency and their association with clinicopathological findings in Indian patients.
    Bhandari P; Ahmad F; Das BR
    Med Oncol; 2017 May; 34(5):92. PubMed ID: 28401483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.
    van der Veer A; Waanders E; Pieters R; Willemse ME; Van Reijmersdal SV; Russell LJ; Harrison CJ; Evans WE; van der Velden VH; Hoogerbrugge PM; Van Leeuwen F; Escherich G; Horstmann MA; Mohammadi Khankahdani L; Rizopoulos D; De Groot-Kruseman HA; Sonneveld E; Kuiper RP; Den Boer ML
    Blood; 2013 Oct; 122(15):2622-9. PubMed ID: 23974192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IKZF1 and CRLF2 gene alterations correlate with poor prognosis in Japanese BCR-ABL1-negative high-risk B-cell precursor acute lymphoblastic leukemia.
    Yamashita Y; Shimada A; Yamada T; Yamaji K; Hori T; Tsurusawa M; Watanabe A; Kikuta A; Asami K; Saito AM; Horibe K
    Pediatr Blood Cancer; 2013 Oct; 60(10):1587-92. PubMed ID: 23804397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IKZF1 Deletion Subtyping and Outcome Analysis in BCR-ABL1-Negative Pediatric B-Cell Acute Lymphoblastic Leukemia: A Single-Institution Experience from North India.
    Gupta SK; Bakhshi S; Gupta R; Sharma P; Pushpam D; Sahoo RK; Kamal VK
    Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):e666-e673. PubMed ID: 33906825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ikaros deletions in BCR-ABL-negative childhood acute lymphoblastic leukemia are associated with a distinct gene expression signature but do not result in intrinsic chemoresistance.
    Vitanza NA; Zaky W; Blum R; Meyer JA; Wang J; Bhatla T; Morrison DJ; Raetz EA; Carroll WL
    Pediatr Blood Cancer; 2014 Oct; 61(10):1779-85. PubMed ID: 24976218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.
    Mullighan CG; Su X; Zhang J; Radtke I; Phillips LA; Miller CB; Ma J; Liu W; Cheng C; Schulman BA; Harvey RC; Chen IM; Clifford RJ; Carroll WL; Reaman G; Bowman WP; Devidas M; Gerhard DS; Yang W; Relling MV; Shurtleff SA; Campana D; Borowitz MJ; Pui CH; Smith M; Hunger SP; Willman CL; Downing JR;
    N Engl J Med; 2009 Jan; 360(5):470-80. PubMed ID: 19129520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.
    Martinelli G; Iacobucci I; Storlazzi CT; Vignetti M; Paoloni F; Cilloni D; Soverini S; Vitale A; Chiaretti S; Cimino G; Papayannidis C; Paolini S; Elia L; Fazi P; Meloni G; Amadori S; Saglio G; Pane F; Baccarani M; Foà R
    J Clin Oncol; 2009 Nov; 27(31):5202-7. PubMed ID: 19770381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IKAROS Gene Deleted B-Cell Acute Lymphoblastic Leukemia in Mexican Mestizos: Observations in Seven Patients and a Short Review of the Literature.
    Ruiz-Delgado GJ; Cantero-Fortiz Y; León-Peña AA; León-González M; Nuñez-Cortés AK; Ruiz-Argüelles GJ
    Rev Invest Clin; 2016; 68(4):210-4. PubMed ID: 27623040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features.
    Schwab CJ; Chilton L; Morrison H; Jones L; Al-Shehhi H; Erhorn A; Russell LJ; Moorman AV; Harrison CJ
    Haematologica; 2013 Jul; 98(7):1081-8. PubMed ID: 23508010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic analysis of Ikaros target genes and tumor suppressor function in BCR-ABL1
    Schjerven H; Ayongaba EF; Aghajanirefah A; McLaughlin J; Cheng D; Geng H; Boyd JR; Eggesbø LM; Lindeman I; Heath JL; Park E; Witte ON; Smale ST; Frietze S; Müschen M
    J Exp Med; 2017 Mar; 214(3):793-814. PubMed ID: 28190001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Illegitimate RAG-mediated recombination events are involved in IKZF1 Δ3-6 deletion in BCR-ABL1 lymphoblastic leukaemia.
    Dong Y; Liu F; Wu C; Li S; Zhao X; Zhang P; Jiao J; Yu X; Ji Y; Zhang M
    Clin Exp Immunol; 2016 Sep; 185(3):320-31. PubMed ID: 27198500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia.
    Steeghs EMP; Boer JM; Hoogkamer AQ; Boeree A; de Haas V; de Groot-Kruseman HA; Horstmann MA; Escherich G; Pieters R; den Boer ML
    Sci Rep; 2019 Mar; 9(1):4634. PubMed ID: 30874617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia?
    Palmi C; Valsecchi MG; Longinotti G; Silvestri D; Carrino V; Conter V; Basso G; Biondi A; Kronnie GT; Cazzaniga G
    Haematologica; 2013 Aug; 98(8):1226-31. PubMed ID: 23585525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.
    Mullighan CG; Miller CB; Radtke I; Phillips LA; Dalton J; Ma J; White D; Hughes TP; Le Beau MM; Pui CH; Relling MV; Shurtleff SA; Downing JR
    Nature; 2008 May; 453(7191):110-4. PubMed ID: 18408710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Significance of IKZF1 gene copy number abnormalities in BCR/ABL-negative B-lineage acute lymphoblastic leukemia in children].
    Zou Y; Liu XM; Zhang L; Chen YM; Guo Y; Chen XJ; Yang WY; Wang SC; Ruan M; Liu TF; Zhang JY; Liu F; Qi BQ; Zhu XF
    Zhongguo Dang Dai Er Ke Za Zhi; 2015 Nov; 17(11):1154-9. PubMed ID: 26575870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Significance of ikaros family zinc finger 1 deletion in pediatric B-acute lymphoblastic leukemia without reproducible cytogenetic abnormalities].
    Liu X; Zhang L; Zou Y; Chang L; Wei W; Ruan M; Chen Y; Yang W; Chen X; Guo Y; Wang S; Liu T; Zhang J; Liu F; Qi B; An W; Zhu X
    Zhonghua Er Ke Za Zhi; 2016 Feb; 54(2):126-30. PubMed ID: 26875463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAS pathway mutation is an added-value biomarker in pediatric Philadelphia-negative B-cell acute lymphoblastic leukemia with IKZF1 deletions.
    Huang YJ; Liu HC; Jaing TH; Wu KH; Wang SC; Yen HJ; Hsiao CC; Chen SH; Lin PC; Yeh TC; Sheen JM; Chen YC; Chang TK; Huang FL; Chao YH; Hou JY; Yang CP; Lin TH; Shih LY
    Pediatr Blood Cancer; 2021 Apr; 68(4):e28899. PubMed ID: 33522704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.